Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DAVID F. Archer

Showing results (71-80 of 175) with videos related to

Pageof 18
Sort By:
American Journal of Obstetrics and Gynecology|December 27, 2008
A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopauseDavid F Archer, Larry Seidman, Ginger D Constantine, et al.
Contraception|January 13, 2009
Effects of progesterone, levonorgestrel and medroxyprogesterone acetate on apoptosis in human endometrial endothelial cellsChainarong Choksuchat, Shumei Zhao, Todd D Deutch, et al.
Expert Review of Endocrinology & Metabolism|September 19, 2019
Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopauseDavid F Archer, James A Simon, David J Portman, et al.
Maturitas|April 4, 2015
17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence reviewSebastian Mirkin, Julia M Amadio, Brian A Bernick, et al.
American Journal of Obstetrics and Gynecology|January 27, 2009
Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safetyDavid F Archer, Caroline M Dupont, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|March 11, 2015
Incidence of endometrial spotting or bleeding during continuous-combined estrogen-progestin therapy in postmenopausal women with and without hypertensionIntira Sriprasert, Hind Beydoun, Vanessa Barnabei, et al.
Contraception|September 3, 2013
Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper armVera Halpern, Stephanie L Combes, Laneta J Dorflinger, et al.
Menopause (New York, N.Y.)|February 13, 2014
Differential effects of menopausal therapies on the endometriumSebastian Mirkin, David F Archer, Hugh S Taylor, et al.
Menopause (New York, N.Y.)|January 19, 2017
Science of intracrinology in postmenopausal womenFernand Labrie, Alain Bélanger, Georges Pelletier, et al.
Expert Opinion on Drug Safety|July 1, 2017
Safety and benefit considerations for menopausal hormone therapyJames H Pickar, David F Archer, Risa Kagan, et al.
Pageof 18

Showing results (71-80 of 175) with videos related to

Sort By:
Pageof 18
American Journal of Obstetrics and Gynecology|December 27, 2008
A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopauseDavid F Archer, Larry Seidman, Ginger D Constantine, et al.
Contraception|January 13, 2009
Effects of progesterone, levonorgestrel and medroxyprogesterone acetate on apoptosis in human endometrial endothelial cellsChainarong Choksuchat, Shumei Zhao, Todd D Deutch, et al.
Expert Review of Endocrinology & Metabolism|September 19, 2019
Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopauseDavid F Archer, James A Simon, David J Portman, et al.
Maturitas|April 4, 2015
17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence reviewSebastian Mirkin, Julia M Amadio, Brian A Bernick, et al.
American Journal of Obstetrics and Gynecology|January 27, 2009
Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safetyDavid F Archer, Caroline M Dupont, Ginger D Constantine, et al.
Menopause (New York, N.Y.)|March 11, 2015
Incidence of endometrial spotting or bleeding during continuous-combined estrogen-progestin therapy in postmenopausal women with and without hypertensionIntira Sriprasert, Hind Beydoun, Vanessa Barnabei, et al.
Contraception|September 3, 2013
Pharmacokinetics of subcutaneous depot medroxyprogesterone acetate injected in the upper armVera Halpern, Stephanie L Combes, Laneta J Dorflinger, et al.
Menopause (New York, N.Y.)|February 13, 2014
Differential effects of menopausal therapies on the endometriumSebastian Mirkin, David F Archer, Hugh S Taylor, et al.
Menopause (New York, N.Y.)|January 19, 2017
Science of intracrinology in postmenopausal womenFernand Labrie, Alain Bélanger, Georges Pelletier, et al.
Expert Opinion on Drug Safety|July 1, 2017
Safety and benefit considerations for menopausal hormone therapyJames H Pickar, David F Archer, Risa Kagan, et al.
Pageof 18